Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive and severe interstitial lung diseases (ILDs) for which there is no cure. IPF is characterized by an excessive accumulation of fibroblasts which secrete an abundance of extracellular proteins such as collagen. These processes lead to repetitive tissue scarring and fibrosis in the lung parenchyma. As a result, lungs become rigid limiting oxygen intake and gas exchange. Once diagnosed, IPF is fatal within 2-3 years. There is no known cause or proven treatment that significantly improves outcomes. Although the cause is unknown, the current model of IPF suggests that an overactive epithelial repair mechanism caused by genetic and epigenetic factors as well as environmental exposures is responsible for the chronic fibrosis and scarring characteristic of IPF. The transforming growth factor beta (TGF-B) signaling pathway has been implicated as a major contributor in activating this chronic fibrosis. An upstream activator of the TGF-B pathway, avB6, has been identified as a potential therapeutic target. My collaborators in Dr. David Baker's lab at the University of Washington have created a novel avB6 integrin inhibitor (BP2_disulf) whose efficacy in improving IPF outcomes has yet to be tested. In my study, I test the ability of BP2_disulf to combat IPF through the use of the standard IPF murine model and translatable end points like non-invasive uCT scans, pulmonary function tests, bronchoalveolar lavage fluid (BALF) profiles, and histology. With these methods, I demonstrate that intraperitoneal injection of BP2_disulf in bleomycin-injured mice has the ability to decrease rate of fibrotic progression and pulmonary function decline compared to mice treated with bleomycin alone. These results prove that BP2_disulf is a promising therapeutic not only for IPF but other ILDs as well. Further efficacy validation and investigation into an aerosolized delivery method will advance this drug to clinical trials and make it accessible to those in need.

L’étude de l’intégrine alphaE(CD103)beta7, exprimée à la surface des lymphocytes T cytotoxiques (CTL) et ayant pour ligand la E cadhérine, marqueur des cellules épithéliales, a permis de démontrer son rôle dans le recrutement des CTL dans la tumeur, la formation de la synapse immunologique et l'induction de la mort des cellules tumorales épithéliales par les CTL spécifiques. Dans ce contexte, nous avons étudié la signalisation de CD103, et ainsi démontré que la paxilline, une protéine des points d'adhésion focaux, interagit avec CD103. De plus, son inhibition diminue les capacités d'adhésion et d'étalement des CTL sur un tapis d'E cadhérine recombinante humaine. Nous avons ensuite identifié le domaine cytoplasmique de CD103 nécessaire à son activation. Une protéine de fusion CD103-GFP a été construite, ainsi que plusieurs mutants du domaine cytoplasmique de CD103. Nous avons identifié le motif ESIRKAQL, nécessaire à l'activation des lymphocytes T. La sérine en position 1163, présente dans ce motif, semble indispensable à la relocalisation de CD103, des lysosomes et de la paxilline, à la zone de contact avec la E-cadhérine. / The alphaE(CD103)beta7 integrin plays a crucial role in the formation of a functional immune synapse (IS) between T cells and epithelial target cells. Indeed, the interaction of CD103 on tumor-infiltrating T lymphocyte (TIL) with its ligand, the epithelial cell marker E cadherin on tumor cells, promotes tumor cell killing. We studied CD103 signaling, and we showed that paxillin, a protein found in focal adhesion, interacts with CD103, and its inhibition leads to a decrease in T cell adhesion and spreading of T cell upon activation with immobilized recombinant E-cadherin-Fc. Secondly, we investigated CD103 cytoplasmic domains involved in its activation. Therefore, we used wild-type (WT)-CD103-GFP or various mutant CD103-GFP fusion proteins. Our results showed that ESIRKAQL intracellular motif is necessary for T cell activation, and in particular the serine in position 1163 that is essential for CD103 clustering and paxillin recruitment.

La thrombasthénie de Glanzmann (TG) est une maladie autosomique récessive liée à undéficit quantitatif et/ou qualitatif de l’intégrine αIIbβ3, principale glycoprotéine présente à la surfacedes plaquettes. Ce complexe sert de récepteur au fibrinogène plasmatique, permettant ainsi auxplaquettes de s’agréger entre-elles. Notre étude visait à caractériser les anomalies génétiquesresponsables de TG chez 76 familles d’origine différente. Les signes hémorragiques présentés parles patients étaient principalement des épistaxis, des pétéchies, des saignements gastro-intestinauxou des ménorragies. Les mutations présentes dans les gènes ITGA2B ou ITGB3 ont été identifiéespar séquençage direct. Tous les exons, ainsi que les régions introniques flanquantes, ont étéétudiées, permettant ainsi d’identifier 78 variations génétiques, dont 57 n’avaient jamais étérapportées. Des mutations tronquantes ou de l’épissage étaient présentes dans près de la moitié descas. Les mutations faux-sens représentaient également une forte proportion des anomaliesmoléculaires retrouvées (50% environ). Le caractère délétère de ces mutations a été confirmé parl’utilisation de méthodes in silico et/ou in vitro, permettant de caractériser les domaines essentiels àla structure et à la fonction des sous-unités αIIb et β3. En termes de corrélation génotype-phénotype,notre étude n’a pas permis de mettre en évidence d’association claire entre certaines mutations et lesyndrome hémorragique présenté par les patients. Cependant, ce travail permet de mieuxcomprendre les mécanismes impliqués dans la structure et le fonctionnement de la principaleintégrine plaquettaire. / Glanzmann thrombasthenia (GT) is a rare autosomal recessive disorder characterized byquantitative and/or qualitative defect of the platelet αIIbβ3 integrin. Naturally occurring mutations inITGA2B or ITGB3 genes are responsible for the disease. Sanger sequencing analysis was applied tomutation screening of 83 diagnosed GT patients. 78 different sequence variations were identified ofwhich 57 had never been previously described. Among the novel identified mutations, truncative,missense and splice site mutations were observed. Therefore, we have identified a spectrum ofunreported mutations that may be of value to decipher the role of specific regions within αIIbβ3.

Chronic inflammation is a triggering mechanism for many metabolic diseases including atherosclerosis and diabetes. A critical step in the development of chronic inflammation is the accumulation of classically activated pro-inflammatory macrophages in the extracellular matrix (ECM) of peripheral tissues. Recently, we demonstrated that adhesion receptor integrin αDβ2 is upregulated on macrophages in atherosclerotic lesions and inflamed adipose tissue, and promotes the development of atherosclerosis and insulin resistance. This pathophysiological mechanism is mediated by αDβ2-dependent strong adhesion of macrophages to the inflamed ECM, which promotes macrophage retention at the site of inflammation. Typical healthy ECM has a limited ligand capacity for integrin αDβ2. However, we recently found that the end-product of DHA oxidation, 2-(ω-carboxyethyl)pyrrole (CEP) serves as ligand for αDβ2. CEP is preferentially generated during inflammation-mediated oxidation and forms adduct with ECM proteins. CEP-modified proteins are detected in inflamed tissue during atherosclerosis, insulin resistance and pathological angiogenesis. In this project, we propose a new strategy for the treatment of chronic inflammation by targeting macrophage retention in the inflamed tissue by focusing on the development of the inhibitor, which is exclusively specific for αDβ2-CEP interaction. The advantage of CEP as a new therapeutic target resides in its unique formation in inflamed tissue. Using specially designed peptide library, protein-protein interaction measured by Biacore and adhesion assay with integrin-transfected HEK293 cells, we identified a sequence (called P5-peptide), which significantly inhibited αD-CEP binding. In vitro three-dimensional migration assay demonstrated that P5 peptide regulates macrophage migration within ECM but not the transendothelial migration of monocytes. The injection of cyclic P5 peptide in the model of thioglycollate-induced peritoneal inflammation led to 3-fold reduction in the number of macrophages accumulated in the peritoneal cavity after 72 hours. Interestingly, P5 peptide injection had no effect on the accumulation of macrophages in αD-deficient mice, that confirmed the specificity of inhibition. This inhibition only affects the recruitment of macrophages, while it has no effect on the efflux of macrophage from the peritoneal cavity in our in vivo studies. The tracking of adoptively transferred fluorescently-labeled WT and αD-/- monocytes in mice on a high fat diet revealed that αD-deficiency reduced 3 folds the accumulation of macrophages in the adipose tissue. The injection of P5 peptide in this model demonstrated the marked reduction of adoptively transferred WT macrophages in adipose tissue. Taken together, these results demonstrate the importance of αDβ2-CEP interaction for the accumulation of infiltrating macrophages during inflammation and propose P5 peptide as a potential inhibitor of atherogenesis and diabetes. Further studies are required to develop these results.

β-Adrenergic receptor (β-AR) stimulation induces cardiac myocyte apoptosis and plays an important role in myocardial remodeling. Here we investigated expression of various apoptosis-related genes affected by β-AR stimulation, and examined first time the role of ataxia telangiectasia mutated kinase (ATM) in cardiac myocyte apoptosis and myocardial remodeling following β-AR stimulation. cDNA array analysis of 96 apoptosis-related genes indicated that β-AR stimulation increases expression of ATM in the heart. In vitro, RT-PCR confirmed increased ATM expression in adult cardiac myocytes in response to β-AR stimulation. Analysis of left ventricular structural and functional remodeling of the heart in wild-type (WT) and ATM heterozygous knockout mice (hKO) 28 days after ISO-infusion showed increased heart weight to body weight ratio in both groups. M-mode echocardiography showed increased percent fractional shortening (%FS) and ejection fraction (EF%) in both groups 28 days post ISO-infusion. Interestingly, the increase in %FS and EF% was significantly lower in the hKO-ISO group. Cardiac fibrosis and myocyte apoptosis were higher in hKO mice at baseline and ISO-infusion increased fibrosis and apoptosis to a greater extent in hKO-ISO hearts. ISO-infusion increased phosphorylation of p53 (Serine-15) and expression of p53 and Bax to a similar extent in both groups. hKO-Sham and hKO-ISO hearts exhibited reduced intact β1 integrin levels. MMP-2 protein levels were significantly higher, while TIMP-2 protein levels were lower in hKO-ISO hearts. MMP-9 protein levels were increased in WT-ISO, not in hKO hearts. In conclusion, ATM plays a protective role in cardiac remodeling in response to β-AR stimulation.

Background: STAT3 is increasingly becoming known for its non-transcriptional regulation of mitochondrial bioenergetic function upon activation of its S727 residue (S727-STAT3). Lengthy mitochondrial dysfunction can lead to cell death. We tested whether an integrin-FAK-STAT3 signaling pathway we recently discovered regulates mitochondrial function and cell survival, and treatments thereof. Methods: Cultured mouse brain bEnd5 endothelial cells were treated with integrin, FAK or STAT3 inhibitors, FAK siRNA, as well as integrin and STAT3 activators. STAT3 null cells were transfected with mutant STAT3 plasmids. Outcome measures included oxygen consumption rate for mitochondrial bioenergetics, Western blotting for protein phosphorylation, mitochondrial membrane potential for mitochondrial integrity, ROS production, and cell counts. Results: Vitronectin-dependent mitochondrial basal respiration, ATP production, and maximum reserve and respiratory capacities were suppressed within 4 h by RGD and αvβ3 integrin antagonist peptides. Conversely, integrin ligands vitronectin, laminin and fibronectin stimulated mitochondrial function. Pharmacological inhibition of FAK completely abolished mitochondrial function within 4 h while FAK siRNA treatments confirmed the specificity of FAK signaling. WT, but not S727A functionally dead mutant STAT3, rescued bioenergetics in cells made null for STAT3 using CRISPR-Cas9. STAT3 inhibition with stattic in whole cells rapidly reduced mitochondrial function and mitochondrial pS727-STAT3. Stattic treatment of isolated mitochondria did not reduce pS727 whereas more was detected upon phosphatase inhibition. This suggests that S727-STAT3 is activated in the cytoplasm and is short-lived upon translocation to the mitochondria. FAK inhibition reduced pS727-STAT3 within mitochondria and reduced mitochondrial function in a non-transcriptional manner, as shown by co-treatment with actinomycin. Treatment with the small molecule bryostatin-1 or hepatocyte growth factor (HGF), which indirectly activate S727-STAT3, preserved mitochondrial function during FAK inhibition, but failed in the presence of the STAT3 inhibitor. FAK inhibition induced loss of mitochondrial membrane potential, which was counteracted by bryostatin, and increased superoxide and hydrogen peroxide production. Bryostatin and HGF reduced the substantial cell death caused by FAK inhibition over a 24 h period. Conclusion: These data suggest that extracellular matrix molecules promote STAT3-dependent mitochondrial function and cell survival through integrin-FAK signaling. We furthermore show a new treatment strategy for cell survival using S727-STAT3 activators.

Neural stem cells are capable of differentiating into three major neural cell types, but the underlying molecular mechanisms remain unclear. Here, we investigated the mechanism by which integrin β4 modulates mouse neural stem cell differentiation in vitro. Inhibition of endogenous integrin β4 by RNA interference inhibited the cell differentiation and the expression of fibroblast growth factor receptor 2 but not fibroblast growth factor receptor 1 or fibroblast growth factor receptor 3. Overexpression of integrin β4 in neural stem cells promoted neural stem cell differentiation. Furthermore, integrin β4-induced differentiation of neural stem cells was attenuated by SU5402, the inhibitor of fibroblast growth factor receptors. Finally, we investigated the role of integrin β4 in neural stem cell survival: knockdown of integrin β4 did not affect survival or apoptosis of neural stem cells. These data provide evidence that integrin β4 promotes differentiation of mouse neural stem cells in vitro possibly through fibroblast growth factor receptor 2.

Recently, the specific roles of integrin β4 in the signaling networks that drive pathological angiogenesis and tumor progression have been revealed. Our previous study showed that integrin β4 might be involved in neuron survival signal transduction. To further our study on the role of integrin β4 in the survival and apoptosis of primary cultured mouse neurons, we inhibited the expression of integrin β4 by its specific small interfering RNA. Viability of the cells remarkably declined, and neurons underwent apoptosis with down-regulation of integrin β4. Next, we investigated the effect of siRNA-mediated down-regulation of integrin β4 on the level of intracellular reactive oxygen species and the activities of NADPH oxidase and superoxide dismutase. The level of reactive oxygen species in the neurons was elevated significantly, the activities of manganese-dependent superoxide dismutase and copper/zinc-dependent superoxide dismutase were not altered, but the activity of NADPH oxidase was increased. Furthermore, inhibition of NADPH oxidase by its specific inhibitor dibenziodolium chloride attenuated the neuronal death induced by integrin β4 knockdown. The data suggest that integrin β4 is a key factor in neuron survival and apoptosis and indicate that this integrin subunit might perform its action through regulating NADPH oxidase and the level of reactive oxygen species in neuronal survival and apoptosis.

To understand whether integrin β4 is involved in vascular endothelial cell (VEC) senescence, we examined integrin β4 level changes, as well as P53 and reactive oxygen species (ROS) levels and alterations of phosphatidylcholine-specific phospholipase C (PC-PLC) activity before and after knocking-down integrin β4 by small interfering RNA. We found integrin β4, P53 and ROS levels increased significantly, while Ca2+-independent PC-PLC activity obviously decreased during VEC senescence. On the other hand, integrin β4 down-regulation attenuated the senescence phenotype and reversed Ca2+-independent PC-PLC activity, and P53 and ROS levels. The data suggested that integrin β4 might mediate VEC senescence through depressing Ca2+-independent PC-PLC and elevating the levels of P53 and ROS.

Previously, we found that 3,4-(methylenedioxy)-1-(2′,3′- epoxypropyl)-benzene (safrole oxide) induced a typical apoptosis in A549 human lung cancer cells by activating caspase-3, -8, and -9. In this study, we further investigated which upstream pathways were activated by safrole oxide during the apoptosis. Immunofluorescence assay combined with laser scanning confocal microscopy revealed that both Fas and Fas ligand (FasL) were up-regulated by the small molecule. In addition, Fas protein distribution was altered, showing a clustering distribution instead of a homogeneous one. Subsequently, Western blot analysis confirmed the up-regulations of Fas and its membrane-binding form of FasL (m-FasL), as well as P53 protein. Conversely, safrole oxide hardly affected integrin β4 subunit expression or distribution, which was reflected from the data obtained by immunofluorescence assay combined with laser scanning confocal microscopy. The results suggested that Fas/FasL pathway might be involved in safrole oxide-induced apoptosis of A549 cells, while integrin β4 might be irrelevant to the apoptosis. Nevertheless, we first found the strong expression of integrin β4 in A549 cells. The study first suggested that safrole oxide might be used as a small molecular promoter of Fas/FasL pathway to elicit apoptosis in A549 cells, which would lay the foundation for us to insight into the new strategies for lung cancer therapy.